HUE046646T2 - 5-bróm-2,6-di-(1H-pirazol-1-il)pirimidin-4-amin rák kezelésénél történõ alkalmazásra - Google Patents

5-bróm-2,6-di-(1H-pirazol-1-il)pirimidin-4-amin rák kezelésénél történõ alkalmazásra

Info

Publication number
HUE046646T2
HUE046646T2 HUE16766384A HUE16766384A HUE046646T2 HU E046646 T2 HUE046646 T2 HU E046646T2 HU E16766384 A HUE16766384 A HU E16766384A HU E16766384 A HUE16766384 A HU E16766384A HU E046646 T2 HUE046646 T2 HU E046646T2
Authority
HU
Hungary
Prior art keywords
pyrazol
pyrimidin
bromo
cancer
amine
Prior art date
Application number
HUE16766384A
Other languages
English (en)
Hungarian (hu)
Inventor
Sanela Bilic
Gomez Juan Alberto Camacho
John Scott Cameron
Laria Julio Cesar Castro-Palomino
Howard, Jr
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Publication of HUE046646T2 publication Critical patent/HUE046646T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE16766384A 2015-08-11 2016-08-10 5-bróm-2,6-di-(1H-pirazol-1-il)pirimidin-4-amin rák kezelésénél történõ alkalmazásra HUE046646T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382425 2015-08-11
US201662335984P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
HUE046646T2 true HUE046646T2 (hu) 2020-03-30

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16766384A HUE046646T2 (hu) 2015-08-11 2016-08-10 5-bróm-2,6-di-(1H-pirazol-1-il)pirimidin-4-amin rák kezelésénél történõ alkalmazásra

Country Status (13)

Country Link
JP (1) JP6964113B2 (ja)
KR (1) KR102226100B1 (ja)
CL (1) CL2018000349A1 (ja)
DK (1) DK3334431T3 (ja)
ES (1) ES2761910T3 (ja)
HK (1) HK1249409B (ja)
HR (1) HRP20192192T1 (ja)
HU (1) HUE046646T2 (ja)
IL (1) IL257350A (ja)
LT (1) LT3334431T (ja)
PT (1) PT3334431T (ja)
RU (1) RU2745560C2 (ja)
ZA (1) ZA201800792B (ja)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.

Also Published As

Publication number Publication date
JP2019218346A (ja) 2019-12-26
RU2745560C2 (ru) 2021-03-29
LT3334431T (lt) 2019-12-27
RU2018108050A (ru) 2019-09-13
ES2761910T3 (es) 2020-05-21
KR20200057790A (ko) 2020-05-26
JP6964113B2 (ja) 2021-11-10
ZA201800792B (en) 2019-06-26
CL2018000349A1 (es) 2018-09-07
IL257350A (en) 2018-03-29
DK3334431T3 (da) 2020-01-02
PT3334431T (pt) 2020-01-06
RU2018108050A3 (ja) 2020-02-17
HRP20192192T1 (hr) 2020-03-06
HK1249409B (zh) 2020-05-08
KR102226100B1 (ko) 2021-03-10

Similar Documents

Publication Publication Date Title
RS59688B1 (sr) 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
IL276733A (en) Use of Aribolin in cancer treatment
HK1231561A1 (zh) 癌症治療
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
IL262143A (en) Improvements in cancer treatment
EP3337784A4 (en) USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
HK1249409B (zh) 用於治療癌症的5-溴-2，6-二-(1h-吡唑-1-基)嘧啶-4-胺
GB201522433D0 (en) Cancer treatment
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment